NCT07216508

Liver Transplant CGM

Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Detailed description

Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.

Conditions

• Liver Transplant
• Post Transplant Diabetes
• Type 2 Diabetes

Interventions

Type	Name	Description
DEVICE	Libre 3+	Blinded CGM will be worn by all participants

Timeline

• Start date: 2025-10-13
• Primary completion: 2026-10-05
• Completion: 2027-10-05
• First posted: 2025-10-14
• Last updated: 2025-11-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study